NeoGenomics Names Warren Stone CEO, Posts Preliminary Q3 Revenue of $209M
NEO has more than doubled off its 52-week low of $7.065.
Summary
NeoGenomics announced Warren Stone will become CEO on January 4, 2027, and disclosed preliminary Q3 revenue of about $209 million with NGS growth of 28%, along with an expected increase to full-year revenue guidance.
Updates
· Seeking Alpha — Shares fell over 12% on Tuesday, and BTIG upgraded NEO to Buy with a $28 target while Needham raised its target to $22.
Key Events · Executive and Board Changes · NEO
-
CEO Succession Formalized
Warren Stone, current President and COO, becomes CEO and a board member effective January 4, 2027. Tony Zook transitions to Executive Chairman on the same date.
-
Preliminary Q3 Revenue of $209M
Preliminary unaudited Q3 2026 revenue is approximately $209 million, with next-generation sequencing (NGS) revenue growth of approximately 28% year-over-year.
-
Full-Year Guidance Increase Expected
The company reiterated full-year revenue and adjusted EBITDA guidance from July 28, 2026, and expects to increase full-year total revenue guidance at the midpoint due to Q3 performance.
-
Executive Compensation Terms
Stone's package: $850,000 base salary, 100% target bonus, and annual equity awards targeting approximately $8 million. Zook's package: $400,000 base salary, 50% target bonus, and annual RSUs targeting approximately $3 million.
Analysis · NEO · Industrial Applications And Services
NeoGenomics formalized its CEO succession plan and disclosed preliminary third-quarter revenue of approximately $209 million, with NGS revenue growing about 28% year-over-year. The company also signaled it expects to raise full-year revenue guidance at the midpoint when it reports Q3 results. The transition from Tony Zook to Warren Stone effective January 4, 2027, had been previously reported, but this filing adds the full compensation packages for both executives and confirms the board expansion to eleven directors. The preliminary revenue figure and guidance increase are the most market-relevant items, as they suggest continued momentum in the oncology diagnostics business.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 28.8% of the 1682 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NEO was trading at $18.93 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $7.07 to $20.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.